Literature DB >> 18809217

Pioglitazone reduces tumor necrosis factor-alpha serum concentration and mRNA expression of adipose tissue in hypercholesterolemic rabbits.

Zhi-hong Wu1, Shui-ping Zhao, Luo-xiang Chu, Hui-jun Ye.   

Abstract

BACKGROUND: Tumor necrosis factor-alpha (TNF-alpha) is an inflammatory cytokine involved in atherogenesis. Adipose tissue is an important source of endogenous TNF-alpha production. Pioglitazone, a member of the thiazolidinediones (TZDs), has anti-inflammatory and anti-atherogenic properties, while underlying mechanism has not been fully elucidated. The aim of this study was to evaluate the effect of pioglitazone on TNF-alpha serum concentration and mRNA expressions of subcutaneous adipose tissue in hypercholesterolemic rabbits.
METHODS: Ten rabbits fed with high-cholesterol diet for 8 weeks were randomly divided into two groups: (1) high cholesterol group (n=5): maintained high cholesterol diet for 4 weeks; (2) pioglitazone group (n=5): the same cholesterol diet plus pioglitazone (3 mg/kg/day) for 4 weeks. Control group (n=5) was fed with normal diet for 12 weeks. Subcutaneous adipose tissue was collected for RNA analysis. The direct effect of pioglitazone on TNF-alpha release was assayed in primary rabbit adipocytes. TNF-alpha levels in serum and adipocytes culture supernatant were measured by ELISA. RT-PCR was used to evaluate TNF-alpha mRNA expressions in adipose tissue and adipocytes.
RESULTS: Compared with control group, rabbits fed with high cholesterol diet showed significantly higher levels of serum total cholesterol (TC), low density lipoprotein cholesterol (LDL-C) and TNF-alpha. Though having no effect on serum glucose level and lipid profile, pioglitazone administration significantly reduced circulating TNF-alpha concentrations, which were positively correlated with TNF-alpha mRNA expressions of adipose tissue (r=0.53, P<0.01). Pioglitazone dose-dependently inhibited lipopolysaccharide (LPS)-induced TNF-alpha secretion and mRNA expression in cultured adipocytes.
CONCLUSION: Pioglitazone significantly reduced serum TNF-alpha level in hypercholesterolemic rabbits independent of its metabolic actions, which may at least partly be due to its direct inhibition of TNF-alpha expression and secretion of adipocytes. This may help to explain the mechanism by which pioglitazone exert anti-atherosclerotic effects. Copyright (c) 2008 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18809217     DOI: 10.1016/j.ijcard.2008.08.009

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  4 in total

1.  Differential effect of concomitant antidiabetic agents on carotid atherosclerosis: a subgroup analysis of the PROLOGUE study.

Authors:  Atsushi Tanaka; Atsushi Kawaguchi; Jun-Ichi Oyama; Tomoko Ishizu; Hiroshi Ito; Jun Fukui; Taizo Kondo; Shigetaka Kuroki; Mamoru Nanasato; Yukihito Higashi; Kohei Kaku; Teruo Inoue; Toyoaki Murohara; Koichi Node
Journal:  Heart Vessels       Date:  2018-10-03       Impact factor: 2.037

2.  A pilot dose finding study of pioglitazone in autistic children.

Authors:  Lucia Capano; Annie Dupuis; Jessica Brian; Deepali Mankad; Lisa Genore; Rianne Hastie Adams; Sharon Smile; Toni Lui; Dina Odrobina; Jane A Foster; Evdokia Anagnostou
Journal:  Mol Autism       Date:  2018-11-26       Impact factor: 7.509

3.  Impact of Metformin and Pioglitazone on Serum Level of Tumor Necrosis Factor-Alpha and Lipid Profiles during Implantation Window in Diabetic Rats.

Authors:  Abbas Bakhteyari; Parvaneh Nikpour; Fatemah Sadat Mostafavi; Nahid Eskandari; Mohammad Matinfar; Sara Soleimani Asl; Roshanak Aboutorabi
Journal:  Int J Fertil Steril       Date:  2019-04-27

4.  Pioglitazone improves in vitro viability and function of endothelial progenitor cells from individuals with impaired glucose tolerance.

Authors:  Valentina Spigoni; Angela Picconi; Monia Cito; Valentina Ridolfi; Sabrina Bonomini; Chiara Casali; Ivana Zavaroni; Luigi Gnudi; Marco Metra; Alessandra Dei Cas
Journal:  PLoS One       Date:  2012-11-05       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.